Meet The Professors 2004 VOL 3, ISSUE 2

You are here: Home: Meet The Professors Vol. 3 Issue 2 2005: Case 3: Select publications

Albain K et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG- 8814). San Antonio Breast Cancer Symposium 2004;Abstract 37.

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. San Antonio Breast Cancer Symposium 2003;Abstract 3.

Coombes RC et al. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen — Updated survival analysis. San Antonio Breast Cancer Symposium 2004;Abstract 3.

Gnant M et al. Zoledronic acid effectively counteracts cancer treatment-induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen — Bone density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio Breast Cancer Symposium 2004;Abstract 6.

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Jakesz R et al. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. San Antonio Breast Cancer Symposium 2004;Abstract 2.

Thurlimann B. Letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. First results of IBCSG 18-98/BIG 1-98. Presentation. Primary Therapy of Early Breast Cancer 9^th International Conference. Abstract

Table of Contents

Home

Editor's Note:
Til death do us part

CASE 1: A 36-year-old woman with a family history of breast cancer and a poorly differentiated, node-negative IDC of the breast who wishes to retain her fertility (from the practice of Dr Richard S Zelkowitz)

- Select publications

Case 2: A 48-year-old woman with an ER/PR-negative, HER2-positive invasive ductal carcinoma with 11/16 positive nodes who developed CNS and bone metastases three years after local and adjuvant systemic therapy (from the practice of Dr Leonard J Seigel)

- Select publications

Case 3: A 73-year-old woman with ER/PR-positive, node-positive breast cancer who was switched to exemestane after three years of adjuvant tamoxifen (from the practice of Dr Arnold S Blaustein)

- Select publications

Case 4: A woman in her late forties diagnosed with a small, node-negative breast tumor who developed a sternal metastasis after two and one half years of tamoxifen with a shift in tumor phenotype from the primary lesion (from the practice of Dr Lowell L Hart)

- Select publications

Case 5: A 67-year-old woman a large ER/PR-positive, HER2-negative infiltrating ductal carcinoma with two positive lymph nodes (from the practice of Dr Lawrence A Tepper)

- Select publications

Case 6: A 41-year-old woman with an ER/PR-positive, HER2-negative breast tumor who had significant residual disease after AC and docetaxel neoadjuvant therapy (from the practice of Dr Michael S Wertheim)

- Select publications

Case 7: A 72-year-old woman with high-risk, ER/PR-positive breast cancer who refuses treatment with AIs after experiencing uncommon side effects and who subsequently develops a painful metastatic skin nodule and bone metastases (from the practice of Dr David M Dresdner)

- Select publications

CME Information

Faculty and Affiliations

Editor's Office

Home · Contact Us

Terms of Use and General Disclaimer
Copyright © 2005 Research To Practice. All Rights Reserved